Design, Synthesis and Primary Immunologic Evaluation of M2e-CRM197 Conjugate as a Universal Influenza Vaccine Candidate
-
Published:2021-10-06
Issue:14
Volume:22
Page:1910-1918
-
ISSN:1389-2010
-
Container-title:Current Pharmaceutical Biotechnology
-
language:en
-
Short-container-title:CPB
Author:
Xu Lu1,
Zhang Chun1ORCID,
Zhang Jing2,
Yu Rong1,
Su Zhiguo2
Affiliation:
1. Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China
2. State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China
Abstract
Background:
Influenza is a contagious respiratory illness caused by an acute infection of
influenza viruses, among which influenza A virus causes seasonal epidemic infections nearly every
year. Due to the unpredictability of the evolving influenza A virus and time-consuming vaccine development
cycles, novel universal influenza vaccines designed to induce broadly cross-reactive immune
responses against frequently mutant influenza A virus strains are urgently required.
Objective:
The aim of this study was to synthesize a novel vaccine through the dual-site specific
conjugation of the constant epitope of 23 amino acids (M2e) of the influenza A virus with a highly
immunogenic carrier protein of Cross-Reacting Material (CRM197) under denaturation and to evaluate
its primary immunogenicity in mice.
Methods:
The antigen (M2e) and the carrier protein (CRM197) were linked with different types of
hetero-functionalized linkers, α-Maleimide-ε-Hydrazide Polyethylene Glycol 2k (MAL-PEG-HZ)
and N-β-Maleimidopropionic Acid Hydrazide (BMPH) separately. The immunogenicity of the
M2e-CRM197 conjugates with different types of linkers was evaluated in mice, and the M2especific
total IgG and IgG-isotypes were determined by ELISA.
Results:
Immunogenicity studies revealed that anti-M2e antibody could be induced by the conjugate
products, M2e-PEG-CRM197 and M2e-BMPH-CRM197, by approximately 30 and 90-fold higher
than that of the M2e group. In addition, the anti-M2e antibody level induced by M2e-PEG-CRM197
conjugate was three times higher than that of M2e-BMPH-CRM197 conjugate, and the former could
simultaneously activate both cellular and humoral immune responses.
Conclusions:
The M2e-CRM197 conjugated vaccines we synthesized in this study are highly immunogenic
compared with M2e alone. Besides, evidence presented here indicated that the hydrophilic,
non-immunogenic and biocompatible chain of the cross-linker might be a better choice for the development
of a conjugate vaccine.
Funder
Outstanding Chinese and Foreign Youth Exchange Program-China Association of Science and Technology
Fundamental Research Funds for the Central Universities
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献